Earnings Summary

CureVac’s revenue fell -1.17% since last year same period to $3.12Mn in the Q1 2020. On a quarterly growth basis, CureVac has generated -54.24% fall in its revenue since last 3-months.

CureVac’s net profit fell -11.93% since last year same period to $-23.85Mn in the Q1 2020. On a quarterly growth basis, CureVac has generated 33.73% jump in its net profits since last 3-months.

CureVac’s net profit margin fell -13.26% since last year same period to -764.67% in the Q1 2020. On a quarterly growth basis, CureVac has generated -44.82% fall in its net profit margins since last 3-months.

CureVac’s earning per share (EPS) estimates for the current year stand at -0.28.

CureVac’s earning per share (EPS) jumped 67.53% since last year same period to -0.25 in the Q3 2022. This indicates that the CureVac has generated 67.53% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CureVac’s return on assets (ROA) stands at -0.34.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CureVac’s return on equity (ROE) stands at -0.19.